SCHEMBL2324658

SCHEMBL2324658

O=CC1CC1c1ccc(Br)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 11/20 0.52
MAOB P27338 7/20 0.52
KCNH2 Q12809 2/20 0.52
RCOR1 Q9UKL0 2/20 0.52
KDM1B Q8NB78 1/20 0.52
HTR2C P28335 2/20 0.46
HTR2B P41595 2/20 0.46
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MAOA P21397 4/20 0.38
HRH3 Q9Y5N1 2/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854689 1.00 KDM1A (0.52) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL2827719 1.00 KDM1A (0.52) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL3901979 0.81 HTR2A (0.46) HTR2CHTR2B
SCHEMBL2827113 0.79 KDM1A (0.52) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL4890488 0.79 KDM1A (0.52) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL5139636 0.79 KDM1A (0.52) KDM1AMAOBKCNH2RCOR1KDM1B
SCHEMBL2359931 0.79 HTR2A (0.44) HTR2CHTR2BCYP2C9CYP2C19
SCHEMBL6250772 0.79 KDM1A (0.47) KDM1ACYP2C9MEN1NPC1KMT2A
SCHEMBL11965121 0.79 HTR2A (0.44) HTR2CHTR2BCYP2C9CYP2C19
SCHEMBL2360390 0.79 KDM1A (0.52) KDM1AHTR2CHTR2BHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 US disclosed
WO-2020241626-A1 PYRIDINIUM SALT AND PEST CONTROL AGENT 日本曹達株式会社 2020-12-03 WO disclosed
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 WO disclosed
CN-1027692-C Process for producing dienamide derivative ROUSSEL UCLAF CO (FR) 1995-02-22 CN disclosed
EP-0369762-B1 Pesticides ROUSSEL UCLAF (FR) 1993-12-29 EP disclosed
EP-0369762-A1 Pesticides ROUSSEL-UCLAF (FR) 1990-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 KDM1A 2361/4885MAOB 3307/4885KCNH2 3253/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 KDM1A 2609/4885MAOB 3453/4885KCNH2 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.